Nymox Pharmaceutical annual free cash flow
2016
2018
2019
2020
2021
2022
2023
2024
Nymox Pharmaceutical Free Cash Flow (FCF) History (NYMXF)
Nymox Pharmaceutical reported −$2.6M in free cash flow for fiscal 2024, an increase of $1.5M from the previous fiscal year.
View full Nymox Pharmaceutical company overviewNymox Pharmaceutical free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$2.6M | $1.5M | — | — |
| 2023 | 2023-12-31 | −$4.1M | $1.1M | — | — |
| 2022 | 2022-12-31 | −$5.2M | $4.6M | — | — |
| 2021 | 2021-12-31 | −$9.8M | $224,000 | — | — |
| 2020 | 2020-12-31 | −$10.1M | −$2.6M | — | −201000.00% |
| 2019 | 2019-12-31 | −$7.4M | $407,000 | — | −6405.17% |
| 2018 | 2018-12-31 | −$7.8M | — | — | −2621.07% |
| 2016 | 2016-12-31 | −$4.5M | — | — | −1585.92% |
Nymox Pharmaceutical quarterly free cash flow
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2023 | 2023-12-31 | −$897,000 | $352,000 | — | — |
| Q3 2023 | 2023-09-30 | −$1.3M | $43,000 | — | — |
| Q2 2023 | 2023-06-30 | −$909,000 | −$2.5M | — | — |
| Q1 2023 | 2023-03-31 | −$991,000 | $3.2M | — | — |
| Q4 2022 | 2022-12-31 | −$1.2M | $1.0M | — | — |
| Q3 2022 | 2022-09-30 | −$1.3M | $1.7M | — | — |
| Q2 2022 | 2022-06-30 | $1.6M | $3.5M | — | — |
| Q1 2022 | 2022-03-31 | −$4.2M | −$1.5M | — | — |
| Q4 2021 | 2021-12-31 | −$2.3M | $16.1M | — | — |
| Q3 2021 | 2021-09-30 | −$3.0M | −$15.7M | — | — |
| Q2 2021 | 2021-06-30 | −$1.9M | $262,000 | — | — |
| Q1 2021 | 2021-03-31 | −$2.7M | −$502,000 | — | — |
| Q4 2020 | 2020-12-31 | −$18.4M | — | — | — |
| Q3 2020 | 2020-09-30 | $12.7M | — | — | — |
| Q2 2020 | 2020-06-30 | −$2.2M | — | — | — |
| Q1 2020 | 2020-03-31 | −$2.2M | — | — | −43380.00% |
Nymox Pharmaceutical free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$7.4M to −$2.6M, a net increase of $4.8M. Nymox Pharmaceutical's latest reported quarter, Q4 2023, generated −$897,000 in free cash flow, an increase of $352,000 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Nymox Pharmaceutical source filings ↗